Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) Return on Equity (2016 - 2025)

Dexcom (DXCM) has disclosed Return on Equity for 15 consecutive years, with 0.31% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity rose 2.0% to 0.31% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.31%, a 2.0% increase, with the full-year FY2025 number at 0.34%, up 7.0% from a year prior.
  • Return on Equity was 0.31% for Q4 2025 at Dexcom, up from 0.27% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.37% in Q1 2021 to a low of 0.13% in Q2 2022.
  • A 5-year average of 0.24% and a median of 0.25% in 2025 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: increased 20bps in 2021, then fell -23bps in 2022.
  • Dexcom's Return on Equity stood at 0.14% in 2021, then rose by 27bps to 0.17% in 2022, then surged by 45bps to 0.25% in 2023, then grew by 13bps to 0.28% in 2024, then rose by 8bps to 0.31% in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Return on Equity are 0.31% (Q4 2025), 0.27% (Q3 2025), and 0.24% (Q2 2025).